A Phase 3 interventional study of Cemiplimab and Investigator Choice (IC) Chemotherapy in Squamous Cell Carcinoma (SCC) and Recurrent or Metastatic, Platinum-refractory Cervical Cancer, sponsored by Regeneron Pharmaceuticals. Completed at 105 sites in 14 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-08.
Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment
The primary objective is to compare overall survival (OS) for patients with recurrent or metastatic cervical cancer who have histology of squamous cell carcinoma (SCC) and who have any eligible histology treated with either cemiplimab or investigator's choice (IC) chemotherapy.
The secondary objectives performed among SCC patients and among all eligible histologies (SCC and adenocarcinoma/adenosquamous carcinoma (AC) are:
627 studies on the registry are indexed under Carcinoma, Squamous Cell; 133 are open to participants now.
This study's enrollment of 608 is above the median of 45 across 476 interventional studies indexed under Carcinoma, Squamous Cell.
Browse Carcinoma, Squamous Cell studies →Regeneron Pharmaceuticals is the lead sponsor of 411 studies on the registry; 90 are open to participants now.
Of its 125 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Counted across the registry records on this site, refreshed daily.
The criteria listed below are not intended to contain all considerations relevant to a patient's potential participation in this clinical trial.
Key Inclusion Criteria:
Recurrent, persistent, and/or cervical cancer with squamous cell histology, for which there is not a curative-intent option (surgery or radiation therapy with or without chemotherapy).
Key Exclusion Criteria:
Prior treatment with other systemic immune-modulating agents that was
Note: Other protocol defined Inclusion/Exclusion apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumour measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumour visible on a scan does not by itself rule you out.
The standard rules for measuring tumours on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumour 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumour sample. Some scores count stained tumour cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumour measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumour visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumours on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumour 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumour sample. Some scores count stained tumour cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cemiplimab
Drug: Cemiplimab
Investigator choice (IC) chemotherapy
Drug: Investigator Choice (IC) Chemotherapy
Intravenous (IV) administration every 3 weeks (Q3W)
Also known as: REGN2810, Libtayo
IC chemotherapy options include: 1. Antifolate: Pemetrexed 2. Topoisomerase 1 inhibitor: Topotecan or Irinotecan 3. Nucleoside analogue: Gemcitabine 4. Vinca alkaloid: Vinorelbine The only chemotherapy treatments allowed in the control arm are any of the 5 drugs that are listed as IC options above.
Overall Survival (OS)
Overall survival was defined as the time from randomization to the date of death due to any cause. A participant who had not died was censored at the last known date of contact.
Time frame: From first dose up to 90 following last dose (~42 months)
Overall Survival (OS) in the SCC Population
Overall survival was defined as the time from randomization to the date of death due to any cause. A participant who had not died was censored at the last known date of contact.
Time frame: From first dose up to 90 following last dose (~42 months)
Progression-free Survival (PFS) Assessed by Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST 1.1)
PFS was defined as the time from randomization to the date of the first documented tumor progression (radiographic) or death due to any cause. Participants who did not have a documented tumor progression or death were censored on the date of their last evaluable tumor assessment.
Time frame: Time from randomization to the date of the first documented tumor progression or death due to any cause (assessed up to 40 months)
Objective Response Rate (ORR) Assessed by Investigator Using RECIST 1.1
ORR was defined as the number of participants who achieved complete response (CR) or partial response (PR) as per RECIST 1.1. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeters (mm) (\<1 centimeter \[cm\]). PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: From date of randomization up to 40 months
Duration of Response (DOR) Assessed Per RECIST 1.1
DOR was defined as the time from the date of first response (CR or PR) to the date of the first documented progressive disease (per RECIST 1.1) or death due to any cause. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm (\<1 cm). PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Participants who never progressed while being followed was censored at the last valid tumor measurement. DOR was determined by Kaplan-Meier estimate.
Time frame: Time from the date of first response to the date of the first documented progressive disease or death due to any cause (up to 40 months)
Quality of Life (QoL): Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) of Global Health Status /Quality of Life (GHS/QoL) and Physical Functioning Scales
EORTC QLQ-C30 is a 30-question tool used to assess the overall QoL in cancer participants. It consisted of 15 domains: 1 GHS/QoL scale, 5 functional scales (Physical, role, cognitive, emotional, social), and 9 symptom scales/items (Fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, financial impact). Most items are scored 1 ("not at all") to 4 ("very much") except for the items contributing to the GHS/QoL, which are scored 1 ("very poor") to 7 ("excellent"). A linear transformation was applied to the raw scores so that all transformed scores lie between 0 to 100. For the GHS/QoL and 5 functional scales a high score indicates better global health status/functioning and a negative change from baseline indicated less improvement. For the symptom scales, a high score indicates a higher level of symptoms, and a negative change from baseline indicated an improvement in symptoms.
Time frame: From Cycle 1 Day 1 up to 40 months (Each cycle = 42 days)
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Death
An adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. A Treatment-emergent adverse event (TEAE) was defined as those that are not present at baseline or represent the exacerbation of a pre-existing condition during the on-treatment period. A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life- threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious TEAEs. Number of participants with TEAEs, serious TEAEs, and TEAEs leading to death were reported.
Time frame: From first dose up to 90 following last dose (~36 months)
Number of Participants With New or Worsened Laboratory Results by National Cancer Institute Common Terminology Criteria for Adverse Event (NCI-CTCAE) Grade
Laboratory parameters included hematology, electrolytes, chemistry (other), and liver function. Clinically significant abnormalities were determined by the investigator based on NCI-CTCAE Grade where Grade 1 = Mild, Grade 2 = moderate, Grade 3 = severe; Grade 4 = life threatening or disabling; Grade 5 = death. Participants with at least 1 lab abnormality Graded 3/4 in hematology, electrolytes, chemistry (other), or liver function reported.
Time frame: From first dose up to 90 following last dose (~36 months)
| Milestone | Cemiplimab | Investigator Choice (IC) Chemotherapy |
|---|---|---|
| Started | 304 | 304 |
| Full analysis set (fas) | 304 | 304 |
| Safety analysis set (saf) | 300 | 290 |
| Completed treatment | 38 | 0 |
| Completed | 35 | 0 |
| Not completed | 269 | 304 |
| Withdrew: Adverse event | 17 | 7 |
| Withdrew: Death | 96 | 98 |
| Withdrew: Lost to follow-up | 2 | 2 |
| Withdrew: Non-compliance with study drug | 0 | 2 |
| Withdrew: Participant decision | 35 | 43 |
| Withdrew: Sponsor decision | 1 | 0 |
| Withdrew: Physician decision | 1 | 3 |
| Withdrew: Disease progression | 109 | 121 |
| Withdrew: Withdrawal by subject | 8 | 26 |
| Withdrew: Other | 0 | 2 |
Overall survival was defined as the time from randomization to the date of death due to any cause. A participant who had not died was censored at the last known date of contact.
| Months | Cemiplimab | Investigator Choice (IC) Chemotherapy |
|---|---|---|
| Overall Survival (OS) | 11.7 (9.6 to 13.4) | 8.5 (7.5 to 9.6) |
PFS was defined as the time from randomization to the date of the first documented tumor progression (radiographic) or death due to any cause. Participants who did not have a documented tumor progression or death were censored on the date of their last evaluable tumor assessment.
| Months | Cemiplimab | Investigator Choice (IC) Chemotherapy |
|---|---|---|
| Progression-free Survival (PFS) Assessed by Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST 1.1) | 2.8 (2.6 to 3.9) | 2.9 (2.7 to 3.5) |
ORR was defined as the number of participants who achieved complete response (CR) or partial response (PR) as per RECIST 1.1. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeters (mm) (\<1 centimeter \[cm\]). PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
| Participants | Cemiplimab | Investigator Choice (IC) Chemotherapy |
|---|---|---|
| Objective Response Rate (ORR) Assessed by Investigator Using RECIST 1.1 | 52 | 19 |
DOR was defined as the time from the date of first response (CR or PR) to the date of the first documented progressive disease (per RECIST 1.1) or death due to any cause. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm (\<1 cm). PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Participants who never progressed while being followed was censored at the last valid tumor measurement. DOR was determined by Kaplan-Meier estimate.
| Months | Cemiplimab | Investigator Choice (IC) Chemotherapy |
|---|---|---|
| Duration of Response (DOR) Assessed Per RECIST 1.1 | 18.7 (16.4 to NA) | 7.2 (5.1 to 9.9) |
EORTC QLQ-C30 is a 30-question tool used to assess the overall QoL in cancer participants. It consisted of 15 domains: 1 GHS/QoL scale, 5 functional scales (Physical, role, cognitive, emotional, social), and 9 symptom scales/items (Fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, financial impact). Most items are scored 1 ("not at all") to 4 ("very much") except for the items contributing to the GHS/QoL, which are scored 1 ("very poor") to 7 ("excellent"). A linear transformation was applied to the raw scores so that all transformed scores lie between 0 to 100. For the GHS/QoL and 5 functional scales a high score indicates better global health status/functioning and a negative change from baseline indicated less improvement. For the symptom scales, a high score indicates a higher level of symptoms, and a negative change from baseline indicated an improvement in symptoms.
| Score on a Scale | Cemiplimab | Investigator Choice (IC) Chemotherapy |
|---|---|---|
| Overall: Change from Baseline of EORTC QLQ-C30 GHS/QoL | 0.46 (-2.715 to 3.642) | -8.54 (-13.004 to -4.084) |
| Overall: Changes from Baseline of EORTC QLQ-C30 Physical Functioning | -0.27 (-3.014 to 2.473) | -8.86 (-12.517 to -5.196) |
An adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. A Treatment-emergent adverse event (TEAE) was defined as those that are not present at baseline or represent the exacerbation of a pre-existing condition during the on-treatment period. A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life- threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious TEAEs. Number of participants with TEAEs, serious TEAEs, and TEAEs leading to death were reported.
| Participants | Cemiplimab | Investigator Choice (IC) Chemotherapy |
|---|---|---|
| Participants with any TEAE | 269 | 266 |
| Participants with any Serious TEAE | 96 | 78 |
| Participants with any TEAE leading to Death | 5 | 2 |
Laboratory parameters included hematology, electrolytes, chemistry (other), and liver function. Clinically significant abnormalities were determined by the investigator based on NCI-CTCAE Grade where Grade 1 = Mild, Grade 2 = moderate, Grade 3 = severe; Grade 4 = life threatening or disabling; Grade 5 = death. Participants with at least 1 lab abnormality Graded 3/4 in hematology, electrolytes, chemistry (other), or liver function reported.
| Participants | Cemiplimab | Investigator Choice (IC) Chemotherapy |
|---|---|---|
| Hematology (Grades 3/4) | 84 | 137 |
| Electrolytes (Grades 3/4) | 47 | 32 |
| Chemistry (Other) (Grades 3/4) | 12 | 10 |
| Liver Function (Grades 3/4) | 28 | 23 |
Overall survival was defined as the time from randomization to the date of death due to any cause. A participant who had not died was censored at the last known date of contact.
| Months | Cemiplimab | Investigator Choice (IC) Chemotherapy |
|---|---|---|
| Overall Survival (OS) in the SCC Population | 10.9 (8.9 to 12.9) | 8.8 (7.6 to 9.8) |
Collected over From first dose up to 90 following last dose (~42 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cemiplimab | 234/300 (78%) | 100/300 (33.3%) | 239/300 (79.7%) |
| Chemotherapy* | 249/290 (85.9%) | 84/290 (29%) | 253/290 (87.2%) |
| Chemotherapy to Cemiplimab* | 2/8 (25%) | 1/8 (12.5%) | 4/8 (50%) |
| Event | Cemiplimab | Chemotherapy* | Chemotherapy to Cemiplimab* |
|---|---|---|---|
| VomitingGastrointestinal disorders | 2/300 | 3/290 | 1/8 |
| NauseaGastrointestinal disorders | 2/300 | 0/290 | 1/8 |
| Urinary tract infectionInfections and infestations | 15/300 | 11/290 | 0/8 |
| AnaemiaBlood and lymphatic system disorders | 3/300 | 14/290 | 0/8 |
| Febrile neutropeniaBlood and lymphatic system disorders | 3/300 | 6/290 | 0/8 |
| PyrexiaGeneral disorders | 4/300 | 6/290 | 0/8 |
| PneumoniaInfections and infestations | 5/300 | 3/290 | 0/8 |
| Acute kidney injuryRenal and urinary disorders | 5/300 | 3/290 | 0/8 |
| PyelonephritisInfections and infestations | 4/300 | 3/290 | 0/8 |
| Autoimmune hepatitisHepatobiliary disorders | 4/300 | 0/290 | 0/8 |
| Event | Cemiplimab | Chemotherapy* | Chemotherapy to Cemiplimab* |
|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 79/300 | 128/290 | 0/8 |
| NauseaGastrointestinal disorders | 63/300 | 100/290 | 0/8 |
| PyrexiaGeneral disorders | 36/300 | 62/290 | 2/8 |
| VomitingGastrointestinal disorders | 49/300 | 66/290 | 0/8 |
| ConstipationGastrointestinal disorders | 46/300 | 58/290 | 1/8 |
| FatigueGeneral disorders | 52/300 | 45/290 | 0/8 |
| Decreased appetiteMetabolism and nutrition disorders | 46/300 | 46/290 | 0/8 |
| NeutropeniaBlood and lymphatic system disorders | 9/300 | 45/290 | 0/8 |
| AstheniaGeneral disorders | 35/300 | 45/290 | 0/8 |
| DiarrhoeaGastrointestinal disorders | 35/300 | 41/290 | 1/8 |
The FAS included all randomized participants.
| Age, Continuous(Years) | Cemiplimab | Investigator Choice (IC) Chemotherapy | Total |
|---|---|---|---|
| Mean | 51.1 ± 11.59 | 51.2 ± 11.77 | 51.1 ± 11.67 |
| Sex: Female, Male(Participants) | Cemiplimab | Investigator Choice (IC) Chemotherapy | Total |
|---|---|---|---|
| Female | 304 | 304 | 608 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Cemiplimab | Investigator Choice (IC) Chemotherapy | Total |
|---|---|---|---|
| Hispanic or Latino | 47 | 44 | 91 |
| Not Hispanic or Latino | 251 | 250 | 501 |
| Unknown or Not Reported | 6 | 10 | 16 |
| Race/Ethnicity, Customized(Participants) | Cemiplimab | Investigator Choice (IC) Chemotherapy | Total |
|---|---|---|---|
| White | 193 | 192 | 385 |
| Black or African American | 9 | 12 | 21 |
| Asian | 88 | 88 | 176 |
| American Indian or Alaska Native | 2 | 1 | 3 |
| Other | 8 | 4 | 12 |
| Unknown | 1 | 1 | 2 |
| Not Reported | 3 | 6 | 9 |
Showing the first 100 of 105 sites across 14 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy
Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Data sharing details ↗ · vivli.org
Ran from Sep 2017 to primary completion in Mar 2021, 42 months.
Results were first posted in Apr 2022, 1 year after primary completion.
Of 21 phase 3 interventional studies under Carcinoma, Squamous Cell, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 91. This study's 42 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cemiplimab